114 related articles for article (PubMed ID: 32807652)
1. Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia.
Tatar E; Karatas M; Bozaci I; Ari A; Acar T; Simsek C; Yildirim AM; Yildirim O; Uslu A
Transfus Apher Sci; 2020 Dec; 59(6):102904. PubMed ID: 32807652
[No Abstract] [Full Text] [Related]
2. A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient.
Thammathiwat T; Tungsanga S; Tiankanon K; Torvorapanit P; Chumpangern W; Udomkarnjananun S; Avihingsanon Y; Sriprasart T; Srisawat N; Jutivorakool K; Paitoonpong L; Putcharoen O; Townamchai N
Transpl Infect Dis; 2021 Feb; 23(1):e13388. PubMed ID: 32585765
[TBL] [Abstract][Full Text] [Related]
3. Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey.
Erdem HA; Korkma PE; Çağlayan D; Işıkgöz Taşbakan M; Yamazhan T; Taşbakan MS; Sayıner A; Gökengin D
Turk J Med Sci; 2021 Jun; 51(3):912-920. PubMed ID: 33237663
[TBL] [Abstract][Full Text] [Related]
4. Favipiravir, an antiviral for COVID-19?
Coomes EA; Haghbayan H
J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899
[No Abstract] [Full Text] [Related]
5. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
6. Fingernail lunula luminescence in COVID-19 patients: Is it a favipiravir-related reaction or a novel manifestation of coronavirus infection.
Kutlu Ö; Yılmaz Ş
Photodermatol Photoimmunol Photomed; 2021 Jul; 37(4):343-344. PubMed ID: 33480085
[No Abstract] [Full Text] [Related]
7. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
Sreekanth Reddy O; Lai WF
Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Cheema HA; Ali A; Ali M; Shahid A; Ghafoor MS; Ur Rehman ME; Sah R; Sahra S; Ahmad S
Am J Ther; 2024 May-Jun 01; 31(3):e328-e331. PubMed ID: 37647511
[No Abstract] [Full Text] [Related]
9. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Successful Response to Intravenous Immunoglobulin and Steroid Pulses in a Renal Transplant Recipient With Severe Covid-19 Disease and Associated Acute Allograft Failure.
Rosa-Guerrero P; Trujillo-Aguilera A; Molina J; Navas A; López-Martín C; Jurado A; Rodríguez-Benot A; Torres-De-Rueda Á
Front Immunol; 2021; 12():671013. PubMed ID: 34046038
[TBL] [Abstract][Full Text] [Related]
11. Favipiravir use for SARS CoV-2 infection.
Boretti A
Pharmacol Rep; 2020 Dec; 72(6):1542-1552. PubMed ID: 33108587
[TBL] [Abstract][Full Text] [Related]
12. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
[TBL] [Abstract][Full Text] [Related]
13. Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19.
Ison MG; Scheetz MH
EBioMedicine; 2021 Jan; 63():103204. PubMed ID: 33418497
[No Abstract] [Full Text] [Related]
14. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
Dabbous HM; Abd-Elsalam S; El-Sayed MH; Sherief AF; Ebeid FFS; El Ghafar MSA; Soliman S; Elbahnasawy M; Badawi R; Tageldin MA
Arch Virol; 2021 Mar; 166(3):949-954. PubMed ID: 33492523
[TBL] [Abstract][Full Text] [Related]
15. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.
Takahashi H; Iwasaki Y; Watanabe T; Ichinose N; Okada Y; Oiwa A; Kobayashi T; Moriya M; Oda T
Int J Infect Dis; 2020 Nov; 100():283-285. PubMed ID: 32829044
[TBL] [Abstract][Full Text] [Related]
16. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
Eloy P; Le Grand R; Malvy D; Guedj J
EBioMedicine; 2021 Dec; 74():103663. PubMed ID: 34768087
[No Abstract] [Full Text] [Related]
18. Clinical Characteristics and Outcomes of Pediatric COVID-19 Pneumonia Treated with Favipiravir in a Tertiary Care Center.
Sitthikarnkha P; Phunyaissaraporn R; Niamsanit S; Techasatian L; Saengnipanthkul S; Uppala R
Viruses; 2024 Jun; 16(6):. PubMed ID: 38932238
[TBL] [Abstract][Full Text] [Related]
19. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J
Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854
[No Abstract] [Full Text] [Related]
20. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA
Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
